FDA Clears Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss

Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CYR-064, paving the way for the company to initiate a randomized, placebo-controlled multi-dose Phase 2 clinical trial of its soft mist nasal spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection. There is currently no FDA-approved drug therapy to treat post-viral smell loss.